Cargando…
Impact of COVID-19 therapy on hyperglycemia
The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194500/ https://www.ncbi.nlm.nih.gov/pubmed/35695412 http://dx.doi.org/10.1177/14791641221095091 |
_version_ | 1784726742307438592 |
---|---|
author | Parise, Rachel Deruiter, Jack Ren, Jun Govindarajulu, Manoj Ramesh, Sindhu Nadar, Rishi M Moore, Timothy Dhanasekaran, Muralikrishnan |
author_facet | Parise, Rachel Deruiter, Jack Ren, Jun Govindarajulu, Manoj Ramesh, Sindhu Nadar, Rishi M Moore, Timothy Dhanasekaran, Muralikrishnan |
author_sort | Parise, Rachel |
collection | PubMed |
description | The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality. |
format | Online Article Text |
id | pubmed-9194500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-91945002022-06-14 Impact of COVID-19 therapy on hyperglycemia Parise, Rachel Deruiter, Jack Ren, Jun Govindarajulu, Manoj Ramesh, Sindhu Nadar, Rishi M Moore, Timothy Dhanasekaran, Muralikrishnan Diab Vasc Dis Res Editorial The goal of this study was to analyze the effect of COVID-19 drugs and biologicals on hyperglycemia. A literature search with key terms, such as “COVID-19 drugs and hyperglycemia” and “COVID-19 vaccines and hyperglycemia,” was conducted using PubMed through September 2021. The CDC data were referenced for current COVID-19 profile and statistics. The NIH COVID-19 guidelines were referenced for updated treatment recommendations. Micromedex and UpToDate were used for drug and disease information. Current results suggested that corticosteroids (dexamethasone), remdesivir and antivirals (lopinavir and ritonavir) all have the potential to significantly raise blood glucose levels putting patients at elevated risk for severe complications. In contrary, hydroxychloroquine is associated with hypoglycemia, and tocilizumab decreases inflammation which is associated with improving glucose levels. Other anti-cytokine bioactive molecules are correlated with lower blood glucose in patients with and without diabetes mellitus. Ivermectin, used for mild COVID-19 disease, possesses the potential for lowering blood glucose. Covishield, Pfizer-BioNTech, and Moderna have all been associated with hyperglycemia after the first dose. Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality. SAGE Publications 2022-06-13 /pmc/articles/PMC9194500/ /pubmed/35695412 http://dx.doi.org/10.1177/14791641221095091 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Editorial Parise, Rachel Deruiter, Jack Ren, Jun Govindarajulu, Manoj Ramesh, Sindhu Nadar, Rishi M Moore, Timothy Dhanasekaran, Muralikrishnan Impact of COVID-19 therapy on hyperglycemia |
title | Impact of COVID-19 therapy on hyperglycemia |
title_full | Impact of COVID-19 therapy on hyperglycemia |
title_fullStr | Impact of COVID-19 therapy on hyperglycemia |
title_full_unstemmed | Impact of COVID-19 therapy on hyperglycemia |
title_short | Impact of COVID-19 therapy on hyperglycemia |
title_sort | impact of covid-19 therapy on hyperglycemia |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194500/ https://www.ncbi.nlm.nih.gov/pubmed/35695412 http://dx.doi.org/10.1177/14791641221095091 |
work_keys_str_mv | AT pariserachel impactofcovid19therapyonhyperglycemia AT deruiterjack impactofcovid19therapyonhyperglycemia AT renjun impactofcovid19therapyonhyperglycemia AT govindarajulumanoj impactofcovid19therapyonhyperglycemia AT rameshsindhu impactofcovid19therapyonhyperglycemia AT nadarrishim impactofcovid19therapyonhyperglycemia AT mooretimothy impactofcovid19therapyonhyperglycemia AT dhanasekaranmuralikrishnan impactofcovid19therapyonhyperglycemia |